Abstract
Although CD20×CD3 bispecific antibodies are effective against systemic B-cell lymphomas, their efficacy in central nervous system (CNS) lymphoma is unknown. Here, we report the CD20×CD3 bispecific glofitamab penetrates the blood-brain barrier, stimulates immune-cell infiltration of CNS tumors, and induces clinical responses in patients with secondary CNS.
© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antibodies, Bispecific* / therapeutic use
-
Antigens, CD20 / immunology
-
Blood-Brain Barrier / pathology
-
CD3 Complex / immunology
-
Central Nervous System Neoplasms* / drug therapy
-
Central Nervous System Neoplasms* / immunology
-
Central Nervous System Neoplasms* / pathology
-
Female
-
Humans
-
Lymphoma / drug therapy
-
Lymphoma / immunology
-
Lymphoma / pathology
-
Lymphoma, B-Cell / drug therapy
-
Lymphoma, B-Cell / immunology
-
Lymphoma, B-Cell / pathology
-
Male
-
Middle Aged
Substances
-
Antibodies, Bispecific
-
Antigens, CD20
-
CD3 Complex